Regulation of the Expression and Activity of Glucose and Lactic Acid Metabolism-Related Genes by Protein Kinase C in Skeletal Muscle Cells
スポンサーリンク
概要
- 論文の詳細を見る
Protein kinase C (PKC) modulators are very attractive therapeutic targets in cancer. Since most cancer cells display increased glycolysis, elucidations of the effects of PKC activation on glycolysis is necessary for the development of effective medicine. In the present study, to clarify the role of PKC in the regulation of glycolysis, we examined the effect of phorbol 12-myristate 13-acetate (PMA), a PKC activator, on the expression and activity of glucose and lactic acid metabolism-related genes in human rhabdomyosarcoma cells (RD cells). In parallel to increases in glucose uptake and mRNA levels of glucose transporters (GLUTs) induced by PMA treatment for 6 h, the hexokinase (HK) mRNA level and activity were also significantly increased in RD cells. On the other hand, a significant increase in lactate dehydrogenase (LDH) mRNA level and activity was seen when the cells were incubated with PMA for 24 h, but not for 6 or 12 h, and was associated with lactic acid production. These effects by PMA treatment were markedly suppressed by Bisindolylmaleimide (BIM), a PKC inhibitor. Furthermore, chetomin, a hypoxia-inducible factor 1 (HIF-1) inhibitor, completely abrogated the increment of LDH mRNA level and activity as well as monocarboxylate transporter (MCT) 4, a lactic acid efflux transporter. In conclusion, we found that HK and LDH activity induced by PKC activation was associated with the glucose uptake and lactic acid level and that LDH and MCT4 are modulated by a common factor, HIF-1.
著者
-
Narumi Katsuya
Laboratory of Clinical Pharmaceutics & Therapeutics, Division of Pharmasciences, Faculty of Pharmace
-
Furugen Ayako
Laboratory of Clinical Pharmaceutics & Therapeutics, Division of Pharmasciences, Faculty of Pharmace
-
Kobayashi Masaki
Laboratory of Clinical Pharmaceutics & Therapeutics, Division of Pharmasciences, Faculty of Pharmace
-
Otake Sho
Laboratory of Clinical Pharmaceutics & Therapeutics, Division of Pharmasciences, Faculty of Pharmace
-
Iseki Ken
Laboratory of Clinical Pharmaceutics & Therapeutics, Division of Pharmasciences, Faculty of Pharmace
-
Ogura Jiro
Laboratory of Clinical Pharmaceutics & Therapeutics, Division of Pharmasciences, Faculty of Pharmace
-
Yamaguchi Hiroaki
Laboratory of Clinical Pharmaceutics and Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University
-
Iseki Ken
Laboratory of Clinical Pharmaceutics and Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University
-
Sasaki Shotaro
Laboratory of Clinical Pharmaceutics and Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University
-
Kikutani Yurika
Laboratory of Clinical Pharmaceutics and Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University
-
Watanabe Meguho
Laboratory of Clinical Pharmaceutics and Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University
-
Takahashi Natsuko
Hokkaido Pharmaceutical University School of Pharmacy
-
Otake Sho
Laboratory of Clinical Pharmaceutics and Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University
-
Ogura Jiro
Laboratory of Clinical Pharmaceutics and Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University
-
Furugen Ayako
Laboratory of Clinical Pharmaceutics and Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University
-
Narumi Katsuya
Laboratory of Clinical Pharmaceutics and Therapeutics, Division of Pharmasciences, Faculty of Pharmaceutical Sciences, Hokkaido University
-
Kobayashi Masaki
Laboratory I Nano Process Technology Department, Corporate Reseach and Development, Laboratories Research and Development Group, Pioneer Corporation, 1-1, Fujimi 6 chome, Tsurugashima-shi, Saitama 350-2288, Japan
関連論文
- Regulation of Monocarboxylate Transporter 1 in Skeletal Muscle Cells by Intracellular Signaling Pathways
- Pharmacokinetics of Oral and Intravenous Administration of Digoxin after Intestinal Ischemia-Reperfusion
- Amiodarone Increases the Accumulation of DEA in a Human Alveolar Epithelium-Derived Cell Line(Pharmacology)
- Post-Transcriptional Regulation of Breast Cancer Resistance Protein after Intestinal Ischemia-Reperfusion(Pharmacology)
- A New Method for Determination of Both Thalidomide Enantiomers Using HPLC Systems(Analytical Biochemistry)
- Contribution of Multidrug Resistance-Associated Protein 2 to Secretory Intestinal Transport of Organic Anions(Pharmacology)
- The Mechanism of Carrier-Mediated Transport of Folates in BeWo Cells: The Involvement of Heme Carrier Protein 1 in Placental Folate Transport
- Down-Regulation of Intestinal Multidrug Resistance-Associated Protein 2 in Long-Evans Cinnamon Rats
- Long-Evans Cinnamon (LEC) ラットにおける有機アニオンの胆汁排出機構
- 小腸におけるアミオダロン代謝物の排出機構
- Placental Folate Transport during Pregnancy
- Electron Beam Recording beyond 200Gbit/in^2 Density for Next Generation Optical Disk Mastering
- Multidrug Resistance Protein 2 Implicates Anticancer Drug-Resistance to Sorafenib
- Placental Folate Transport during Pregnancy
- The Mechanism of Carrier-Mediated Transport of Folates in BeWo Cells : The Involvement of Heme Carrier Protein 1 in Placental Folate Transport
- Regulation of Nitrate Reductase by Non-modifiable Derivatives of PII in the Cells of Synechococcus elongatus Strain PCC 7942
- Practical Electron Beam Recorder for High-Density Optical and Magnetic Disk Mastering
- Effect of 5-Fluorouracil Treatment on SN-38 Absorption from Intestine in Rats
- Electron Beam Recording beyond 200 Gbit/in2 Density for Next Generation Optical Disk Mastering
- Regulation of the Expression and Activity of Glucose and Lactic Acid Metabolism-Related Genes by Protein Kinase C in Skeletal Muscle Cells